Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors

Published:2020-09 Issue: Volume:147 Page:221-228
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Umemura Shigeki,Zhu Jianquan,Chahine Joeffrey J.,Kallakury Bhaskar,Chen Vincent,Kim In-Kyu,Zhang Yu-Wen,Goto Koichi,He Yongfeng,Giaccone Giuseppe

Funder

Sandy Daulton Fund

Development of a New Treatment for Small Cell Lung Cancer harboring Rare Molecular Alterations

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference48 articles.

1. Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose;Harnath;J. Thorac. Oncol.,2012

2. Thymoma;Müller-Hermelink;Curr. Opin. Oncol.,2000

3. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery;Margaritora;Ann. Thorac. Surg.,2010

4. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study;Giaccone;Lancet Oncol.,2018

5. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial;Cho;J. Clin. Oncol.,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas;Clinical Lung Cancer;2024-06

2. PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression;Biomedicines;2024-03-31

3. Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas;Cancers;2023-12-29

4. Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village;Molecular Therapy;2023-12

5. Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures;Frontiers in Immunology;2023-10-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3